LAI leadership Pharmathen has one of the most extensive pipelines focused on long-acting injectables (LAI) and sustained-release technologies, presenting multiple opportunities for partnerships, contract manufacturing, and co-development of LAI therapies for psychiatry and other chronic indications.

Global footprint With US FDA and EU-approved manufacturing facilities in Greece and a presence serving customers in over 90 countries, there is significant potential to expand supply agreements, risk-sharing manufacturing, and regional licensing deals to broaden market access.

Strategic acquisitions Recent acquisitions and expansions, including CBL Patras, indicate a growth trajectory and a readiness to integrate vertically, enabling cross-sell of formulation capabilities and end-to-end development and manufacturing services.

R&D investment As a top European pharmaceutical R&D investor with advanced LATT platforms and a diverse portfolio of over 100 products, Pharmathen is a strong candidate for collaborative R&D programs, technology licensing, and long-term product lifecycle management partnerships.

People and partnerships A diverse, female-led research operations team and a broad partner network in 90+ countries create opportunities for consulting, training collaborations, and co-visibility in regional markets to accelerate product launches and market access.